FDA declines review of Moderna’s seasonal flu mRNA vaccine, delaying 2026 launch
On February 11, FDA declined to initiate review of Moderna’s application for its first seasonal flu mRNA vaccine, deferring assessment of the novel candidate. The setback pushes the anticipated regulatory decision past mid-2026 and threatens to delay the vaccine’s planned autumn 2026 rollout.
1. FDA Declines Initial Review
On February 11, FDA notified Moderna that it would not begin the review process for the company’s first seasonal flu mRNA vaccine. The decision reflects FDA’s determination that the current submission requires additional supporting data before evaluation can proceed.
2. Regulatory Timeline Impact
Moderna had targeted a mid-2026 regulatory decision to align with the autumn vaccination season. With FDA declining to review now, the regulatory timeline will slip, likely postponing approval and commercial launch into late 2026 or beyond.
3. Commercial and Financial Implications
The delay interrupts Moderna’s plan to diversify beyond its COVID-19 franchise and capture part of the $4 billion annual flu vaccine market. Investors will closely watch how the postponement affects Moderna’s 2026 growth outlook and R&D spending.
4. Moderna’s Next Steps
Moderna must address the FDA’s concerns by submitting additional preclinical and clinical data. The company aims to file a revised application in the second half of 2026 to regain alignment with the autumn immunization schedule.